Genetics and Genomics of Urological Cancers - Current Guidelines and Case-based Discussion to Guide Clinical Practice Webcast (2024)

This case-based interactive course describes the role of germline genetics in urological cancers and how the identification of an alteration may impact precision oncology. We will provide a concise and comprehensive review of hereditary cancer genetics, discuss genetic risk assessment, diagnosis and treatment for a range of hereditary kidney, adrenal, upper tract and prostate cancer syndromes. We will review current National Comprehensive Cancer Network and AUA Guidelines for genetic evaluation of patients with kidney, adrenal, upper tract and prostate cancers. Additional areas of focus include interpretation of genetics and genomics test results, genetics counseling and components of informed consent for genetic testing. Completion of this course will allow participants to identify patients at high risk of genetic predisposition to urological cancers for timely genetic counseling and testing, enhance participants’ skills in interpreting genetic and genomic test results, and ease the integration of genetic evaluation into routine clinical practice to improve patients’ access to the latest advances in precision medicine.


This educational activity is supported by independent educational grants from:

Astellas, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Lantheus Medical Imaging, Merck & Co., Inc., Novartis Pharmaceuticals Corporation, Pfizer, Inc.

Learning Objectives

At the conclusion of this activity, participants will be able to:

  1.  Describe key components of genetic risk assessment, genetic counseling and informed consent for genetic testing.
  2.  Identify elements of genetic test reports including variant classification, variant allele frequency, gene penetrance, biomarkers and clinical actionability.
  3.  Identify criteria for genetic testing for men with prostate cancer. Understand the clinical implications of genetic result in prostate cancer screening and management of both localized and advanced prostate cancer.
  4.  Recognize genetic causes, tumor features, and cancer risk associated with Lynch syndrome, and apply gained knowledge to improve care of patients with upper tract urothelial carcinoma.
Course summary
Available credit: 
  • 2.00 AMA PRA Category 1 Credit™
  • 2.00 Non-Physician Participation
Course opens: 
Course expires: 


NameCompany NameRelationship TypeEnd Date
Baker, MariaGuardant HealthInvestment InterestCurrent
Exact SciencesInvestment InterestCurrent
NeoGenomicsInvestment Interest08/14/2023
IlluminaInvestment Interest07/10/2023
23andMeInvestment Interest07/10/2023
Shuch, Brian MatthewVeracyteConsultant or AdvisorCurrent
MerckConsultant or AdvisorCurrent
AllogeneScientific Study or Trial01/01/2023
Johnson & JohnsonConsultant or AdvisorCurrent
BeigeneScientific Study or Trial01/01/2023
TelixConsultant or AdvisorCurrent
Siddiqui, Mohummad MinhajNo relevant financial relationships to disclose
Truong, HongNo relevant financial relationships to disclose
Uloko, MariaEndo PharmaceuticalsConsultant or Advisor02/02/2023



PDF icon Education Council Disclosures


PDF icon COI Review Work Group Disclosures

AUA Office of Education Staff has nothing to disclose.

All relevant financial relationships have been mitigated.

Method of Participation: Learners will participate in this online educational activity by viewing the webcast and completing the post-test and evaluation. To claim CME credit for this enduring material, learners must complete the post-test, passing with 80% accuracy, and submit the program evaluation.

Release Date: May, 2024
Expiration Date: May, 2025

Accreditation: The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation: The American Urological Association designates this enduring material for a maximum of 2 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

Other Learners: The AUA is not accredited to offer credit to participants who are not MDs or DOs. However, the AUA will issue documentation of participation that states that the activity was certified for AMA PRA Category 1 Credit™.

Evidence Based Content: It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.

AUA Disclosure Policy: All persons in a position to control the content of an educational activity (i.e., activity planners, presenters, authors) are required to disclose to the provider all financial relationships with any commercial interest (aka ineligible company) during the previous 24 months. The AUA must determine if the individual’s relationships may influence the educational content and mitigate any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners information with which they can make their own judgments.

Mitigation of Identified Conflict of Interest: All disclosures will be reviewed by the AUA Conflict of Interest (COI) Review Work Group Chair and/or Vice Chair for identification of conflicts of interest. The AUA COI Review Work Group, working with Office of Education staff, will document the mechanism(s) for management and mitigation of the conflict of interest and final approval of the activity will be documented prior to implementation. 

Off-label or Unapproved Use of Drugs or Devices: The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.


Disclaimer: The opinions and recommendations expressed by faculty, authors and other experts whose input is included in this program are their own and do not necessarily represent the viewpoint of the AUA.

Reproduction Permission: Reproduction of written materials developed for this AUA course is prohibited without the written permission from individual authors and the American Urological Association.

Available Credit

  • 2.00 AMA PRA Category 1 Credit™
  • 2.00 Non-Physician Participation
Please login or register to take this course.